[The antiparkinson activity of gludantan (preliminary report)].
A total of 33 patients with different forms of parkinsonism were treated by a new original antiparkinsonic preparation Gludantane synthesized at the Institute of Organic Synthesis of the Latvian Academy of Sciences. The authors demonstrated a higher antiparkinsonic activity of this drug compared to cholinolytical preparations and midantane and the possibility of achieving a better therapeutical effect in a combination of gludantane with other antiparkinsonic drugs. The preparation appeared to be effective in different etiological forms of parkinsonism. However, its highest effect was in the rigid and rigid-trembling forms, and less effective in trembling-rigid forms and not effective in the trembling form. Gludantane is practically devoid of side-effects and is well tolerated by patients.
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000008:administration & dosage; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D004295:Dihydroxyphenylalanine; D000547:Amantadine
Ob antiparkinsonicheskoĭ aktivnosti gludantana (predvaritel'noe soobshchenie)